Zoetis (ZTS) stock
Last close $80.79 on 2026-11-19 (-5.59%) · Sector: Healthcare
Zoetis is an American drug company and the world's largest maker of medicines and vaccines for pets and livestock, such as farm animals. It earns most of its money by selling these animal health products to veterinarians, farms, and pet owners.
Zoetis is still profitable, with about $9.5 billion in sales over the last 12 months and a gross margin of about 71.5%, which means it keeps roughly 71 cents of each sales dollar after the direct cost of making its products. The stock has lagged the market badly, down 30.3% over the past year while the S&P 500 rose 9.7%. The shares trade about 39.0% below their 52-week high and have had large drops after earnings reports, including a 21.5% fall in May 2026. Insider activity is mixed: the CEO sold $2.5 million of stock in February 2026, while three directors bought about $0.9 million in May.
Key numbers
- Market cap: $33.3B
- Revenue (last 12 months): $9.49B
- Revenue growth: +0.9%
- Gross margin: 71.5%
- P/E: 13.6
- P/S: 3.5
- Debt to equity: 2.52
- Current ratio: 2.35
Quality score
Overall 10/100 · growth 31 · profitability None · financial health 0 · value 0
Performance and risk
1-year return -30.3% vs S&P 500 +9.7% · volatility 38.7% (S&P 500 13.8%) · largest drop -47.3% · beta 0.64
Stock move the day after earnings
- 2026-02-12: -2.4%
- 2026-05-07: -21.5%
- 2026-08-06: +3.9%
- 2026-11-05: -7.9%
Congress trades (90 days)
3 buys, 0 sells
Insider trades (12 months)
Bought $0.9M · sold $2.5M
ZTS stock research · ZTS options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.